Hi Brushup
Agree in part, I recall using 5 year life cycles for brands and with the heavy investment strategies and the final 3 years planned being cashcow time.
But I think we all know the royalty rate will be small.
It will be interesting to figure out which path the negotiation went for the license. Did they get a marketing % or flat fee reducing the royalty or are all costs deducted (hopefully with a cap)
When it comes to price reaction, I think if history is a guide, pre the original license when we all got excited it went from 3ish to 9c then some months later it jumped on product launch. (also we had the coty and GSK potential coming).
Then we found out it was a trial and price retreated.
2 years later we are about to be at the same point again, but this time with 2 licences (both a wand) at least. So I expect a jump on signing with a product launch some months later to give it another boost.
I am not expecting to see these prices again unless the product fails in the market place
time will tell
- Forums
- ASX - By Stock
- Eye wand
WFL
wellfully limited
Add to My Watchlist
0.00%
!
0.3¢

Hi Brushup Agree in part, I recall using 5 year life cycles for...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
WFL (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online